HEALTHCARE
Global Oncology Market - Industry Trends and Forecast to 2032
REPORT OVERVIEW
Global Oncology Market, By Cancer Types (Breast Cancer, Lung Cancer, Kidney Cancer, Liver Cancer, Ovarian Cancer, Prostate Cancer, Skin Cancer, Pancreatic Cancer, Colorectal Cancer, and Others), Cancer Diagnostics (Tumor Biomarker Test, Imaging, Biopsy, Liquid Biopsy, Immunohistochemistry, In situ Hybridization), Cancer Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy) End-User (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Academia, Specialty Clinics) Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2032.
Market Insights
Market Dynamics
- Government initiatives and funding for cancer research
- Growing awareness about cancer and its treatment options
- High cost of cancer treatments
- Stringent regulatory approvals
- Increasing investment in cancer research and development
- Growing demand for minimally invasive treatments
- Managing the high cost of treatment and care
- Addressing disparities in access to cancer care
SEGMENTATION
- Cancer Types
- Breast Cancer
- Lung Cancer
- Kidney Cancer
- Liver Cancer
- Ovarian Cancer
- Prostate Cancer
- Skin Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Blood Cancer
- Others
- Cancer Diagnostics
- Tumor Biomarker Test
- Imaging
- Biopsy
- Liquid Biopsy
- Immunohistochemistry
- In situ Hybridization
- Cancer Treatment
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Hormonal Therapy
- End-User
- Hospitals
- Diagnostic Laboratories
- Diagnostic Imaging Centers
- Academia
- Specialty Clinics
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- The Netherlands
- Belgium
- Turkey
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Singapore
- Malaysia
- Australia
- Thailand
- Philippines
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Chile
- Colombia
- Rest of South America
- Middle East and Africa
- Kingdom of Saudi Arabia
- South Africa
- U.A.E.
- Egypt
- Rest of Middle East and Africa
KEY MARKET PLAYERS
- Roche Holding AG
- Novartis International AG
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Merck & Co., Inc.
- AstraZeneca PLC
- Johnson & Johnson
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Amgen Inc.
Table OF CONTENTS
- SECTION 1 - INTRODUCTION
- 1.1 Taxonomy
- 1.2 Market Overview
- 1.3 Currency and Limitations
- 1.3.1 Currency
- 1.3.2 Limitations
- 1.4 Key Competitors
- SECTION 2 - RESEARCH METHODOLOGY
- 2.1 Research Approach
- 2.2 Data Collection and Validation
- 2.2.1 Secondary Research
- 2.2.2 Primary Research
- 2.3 Market Assessment
- 2.3.1 Market Size Estimation
- 2.3.2 Bottom-up Approach
- 2.3.3 Top-down Approach
- 2.3.4 Growth Forecast
- 2.4 Market Study Assumptions
- 2.5 Data Sources
- SECTION 3 - EXECUTIVE SUMMARY
- 3.1 Global Oncology Market, by Cancer Types
- 3.2 Global Oncology Market, by Cancer Diagnostics
- 3.3 Global Oncology Market, by Cancer Treatment
- 3.4 Global Oncology Market, by End-User
- 3.5 Global Oncology Market, by Geography
- 3.6 Market Position Grid
- SECTION 4 - PREMIUM INSIGHTS
- 4.1 Regulatory Framework
- 4.1.1 Standards
- 4.1.2 Regulatory Landscape
- 4.2 Value Chain Analysis
- 4.3 Supply Chain Analysis
- 4.4 COVID-19 Impact
- 4.5 Russia-Ukraine War Impact
- 4.6 PORTER's Five Force Analysis
- 4.7 PESTLE Analysis
- 4.8 SWOT Analysis
- 4.9 Go to Market Strategy
- 4.10 Opportunity Orbit
- 4.11 Multivariate Modelling
- 4.12 Pricing Analysis
- SECTION 5 - MARKET DYNAMICS
- 5.1 Trends
- 5.1.1 Increasing prevalence of cancer globally
- 5.1.2 Advancements in cancer diagnostics and treatments
- 5.1.3 Trend 3
- 5.2 Drivers
- 5.2.1 Government initiatives and funding for cancer research
- 5.2.2 Growing awareness about cancer and its treatment options
- 5.2.3 Driver 3
- 5.2.4 Driver 4
- 5.3 Restraints
- 5.3.1 High cost of cancer treatments
- 5.3.2 Stringent regulatory approvals
- 5.3.3 Restraint 3
- 5.4 Opportunities
- 5.4.1 Increasing investment in cancer research and development
- 5.4.2 Growing demand for minimally invasive treatments
- 5.4.3 Opportunity 3
- 5.4.4 Opportunity 4
- 5.5 Challenges
- 5.5.1 Managing the high cost of treatment and care
- 5.5.2 Addressing disparities in access to cancer care
- 5.5.3 Challenge 3
- SECTION 6 - GLOBAL ONCOLOGY MARKET, BY CANCER TYPES
- 6.1 Cancer Types Summary
- 6.2 Market Attractive Index
- 6.3 Global Oncology Market, by Cancer Types (2019-2032)
- SECTION 7 - GLOBAL ONCOLOGY MARKET, BY CANCER DIAGNOSTICS
- 7.1 Cancer Diagnostics Summary
- 7.2 Market Attractive Index
- 7.3 Global Oncology Market, by Cancer Diagnostics (2019-2032)
- SECTION 8 - GLOBAL ONCOLOGY MARKET, BY CANCER TREATMENT
- 8.1 Cancer Treatment Summary
- 8.2 Market Attractive Index
- 8.3 Global Oncology Market, by Cancer Treatment (2019-2032)
- SECTION 9 - GLOBAL ONCOLOGY MARKET, BY END-USER
- 9.1 End-User Summary
- 9.2 Market Attractive Index
- 9.3 Global Oncology Market, by End-User (2019-2032)
- SECTION 10 - GLOBAL ONCOLOGY MARKET, BY GEOGRAPHY
- 10.1 Regional Summary
- 10.2 Market Attractive Index
- 10.3 Global Oncology Market, by Geography (2019-2032)
- SECTION 11 - NORTH AMERICA ONCOLOGY MARKET
- 11.1 North America Summary
- 11.2 Market Attractive Index
- 11.3 North America Oncology Market, by Cancer Types (2019-2032)
- 11.4 North America Oncology Market, by Cancer Diagnostics (2019-2032)
- 11.5 North America Oncology Market, by Cancer Treatment (2019-2032)
- 11.6 North America Oncology Market, by End-User (2019-2032)
- 11.7 North America Oncology Market, by Country (2019-2032)
- 11.7.1 U.S.
- 11.7.2 Canada
- 11.7.3 Mexico
- 11.7.4 Rest of North America
- SECTION 12 - EUROPE ONCOLOGY MARKET
- 12.1 Europe Summary
- 12.2 Market Attractive Index
- 12.3 Europe Oncology Market, by Cancer Types (2019-2032)
- 12.4 Europe Oncology Market, by Cancer Diagnostics (2019-2032)
- 12.5 Europe Oncology Market, by Cancer Treatment (2019-2032)
- 12.6 Europe Oncology Market, by End-User (2019-2032)
- 12.7 Europe Oncology Market, by Country (2019-2032)
- 12.7.1 Germany
- 12.7.2 U.K.
- 12.7.3 France
- 12.7.4 Italy
- 12.7.5 Spain
- 12.7.6 Russia
- 12.7.7 The Netherlands
- 12.7.8 Belgium
- 12.7.9 Turkey
- 12.7.10 Rest of Europe
- SECTION 13 - ASIA-PACIFIC ONCOLOGY MARKET
- 13.1 Asia-Pacific Summary
- 13.2 Market Attractive Index
- 13.3 Asia-Pacific Oncology Market, by Cancer Types (2019-2032)
- 13.4 Asia-Pacific Oncology Market, by Cancer Diagnostics (2019-2032)
- 13.5 Asia-Pacific Oncology Market, by Cancer Treatment (2019-2032)
- 13.6 Asia-Pacific Oncology Market, by End-User (2019-2032)
- 13.7 Asia-Pacific Oncology Market, by Country (2019-2032)
- 13.7.1 China
- 13.7.2 India
- 13.7.3 Japan
- 13.7.4 South Korea
- 13.7.5 Singapore
- 13.7.6 Malaysia
- 13.7.7 Australia
- 13.7.8 Thailand
- 13.7.9 Philippines
- 13.7.10 Rest of Asia-Pacific
- SECTION 14 - SOUTH AMERICA ONCOLOGY MARKET
- 14.1 South America Summary
- 14.2 Market Attractive Index
- 14.3 South America Oncology Market, by Cancer Types (2019-2032)
- 14.4 South America Oncology Market, by Cancer Diagnostics (2019-2032)
- 14.5 South America Oncology Market, by Cancer Treatment (2019-2032)
- 14.6 South America Oncology Market, by End-User (2019-2032)
- 14.7 South America Oncology Market, by Country (2019-2032)
- 14.7.1 Brazil
- 14.7.2 Argentina
- 14.7.3 Chile
- 14.7.4 Colombia
- 14.7.5 Rest of South America
- SECTION 15 - MIDDLE EAST AND AFRICA ONCOLOGY MARKET
- 15.1 Middle East and Africa Summary
- 15.2 Market Attractive Index
- 15.3 Middle East and Africa Oncology Market, by Cancer Types (2019-2032)
- 15.4 Middle East and Africa Oncology Market, by Cancer Diagnostics (2019-2032)
- 15.5 Middle East and Africa Oncology Market, by Cancer Treatment (2019-2032)
- 15.6 Middle East and Africa Oncology Market, by End-User (2019-2032)
- 15.7 Middle East and Africa Oncology Market, by Country (2019-2032)
- 15.7.1 Kingdom of Saudi Arabia
- 15.7.2 South Africa
- 15.7.3 U.A.E.
- 15.7.4 Egypt
- 15.7.5 Rest of Middle East and Africa
- SECTION 16 - COMPANY SHARE ANALYSIS
- 16.1 Global Oncology Market, Company Share Analysis
- 16.2 North America Oncology Market, Company Share Analysis
- 16.3 Europe Oncology Market, Company Share Analysis
- 16.4 Asia-Pacific Oncology Market, Company Share Analysis
- SECTION 17 - COMPANY PROFILES
- 17.1 Roche Holding AG
- 17.1.1 Company Snapshot
- 17.1.2 Financial Overview
- 17.1.3 Product Portfolio
- 17.1.4 Recent Developments
- 17.2 Novartis International AG
- 17.2.1 Company Snapshot
- 17.2.2 Financial Overview
- 17.2.3 Product Portfolio
- 17.2.4 Recent Developments
- 17.3 Bristol-Myers Squibb Company
- 17.3.1 Company Snapshot
- 17.3.2 Financial Overview
- 17.3.3 Product Portfolio
- 17.3.4 Recent Developments
- 17.4 Pfizer Inc.
- 17.4.1 Company Snapshot
- 17.4.2 Financial Overview
- 17.4.3 Product Portfolio
- 17.4.4 Recent Developments
- 17.5 Merck & Co., Inc.
- 17.5.1 Company Snapshot
- 17.5.2 Financial Overview
- 17.5.3 Product Portfolio
- 17.5.4 Recent Developments
- 17.6 AstraZeneca PLC
- 17.6.1 Company Snapshot
- 17.6.2 Financial Overview
- 17.6.3 Product Portfolio
- 17.6.4 Recent Developments
- 17.7 Johnson & Johnson
- 17.7.1 Company Snapshot
- 17.7.2 Financial Overview
- 17.7.3 Product Portfolio
- 17.7.4 Recent Developments
- 17.8 Sanofi S.A.
- 17.8.1 Company Snapshot
- 17.8.2 Financial Overview
- 17.8.3 Product Portfolio
- 17.8.4 Recent Developments
- 17.9 Takeda Pharmaceutical Company Limited
- 17.9.1 Company Snapshot
- 17.9.2 Financial Overview
- 17.9.3 Product Portfolio
- 17.9.4 Recent Developments
- 17.10 Amgen Inc.
- 17.10.1 Company Snapshot
- 17.10.2 Financial Overview
- 17.10.3 Product Portfolio
- 17.10.4 Recent Developments
- SECTION 18 - RELATED REPORTS
- SECTION 19 - DISCLAIMER
RESEARCH METHODOLOGY
RESEARCH AND DATA COLLECTION
- Research articles published on Technium
- Science and MDPI
- Research publications by government approved associations and societies
DATA PRE-PROCESSING
The term "data pre-processing" refers to the collection of procedures and methods used to clean, modify, and make ready for analysis the raw data gathered during research and data collection. The completion of this phase is necessary to guarantee that the data are reliable, consistent, and appropriate for statistical analysis and other data-driven tasks. The data pre-processing ensures that the information gathered from research and data collection is comparable and expressed in standard units, by the integration of missing data pointers and algorithmic approaches.
MODELING AND FORECASTING
QUALITY ASSURANCE AND OUTPUT
Quality assurance and output involves the process of validation, adjustments, further publications of key market indicators. Extensive plausibility and consistency tests are performed on derived time series to ensure the high degree of quality of our market analysis. This quality assurance procedure also includes rigorous inspection, validation, and editing by an experienced management team to assure the dependability of the published data.